Impact of antimicrobial stewardship programme changes on unnecessary double anaerobic coverage therapy

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2655-2658

  Rattanaumpawan, Pinyo ^a   Morales, Knashawn H ^a   Binkley, Shawn ^a   Synnestvedt, Marie ^a   Weiner, Mark G ^a   Gasink, Leanne B ^a,b   Fishman, Neil O ^a   Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Ampicillin sulbactam; Antibiotic stewardship programme; Metronidazole

Indexed keywords

AMPICILLIN; METRONIDAZOLE; SULBACTAM;

ANTIBIOTIC STEWARDSHIP PROGRAMME; ARTICLE; CASE CONTROL STUDY; DOUBLE ANAEROBIC COVERAGE THERAPY; DRUG CONTROL; DRUG USE; HEALTH PROGRAM; HOSPITALIZATION; INAPPROPRIATE PRESCRIBING; RISK FACTOR; SURGICAL WARD; UNNECESSARY PROCEDURE;

AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG UTILIZATION; HOSPITALS; HUMANS; INAPPROPRIATE PRESCRIBING; METRONIDAZOLE; PHYSICIAN'S PRACTICE PATTERNS; SULBACTAM;

EID: 80054679923     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr321     Document Type: Article

References (10)

1. Brook I. Treatment of anaerobic infection. Expert Rev Anti Infect Ther 2007; 5: 991-1006.
2. Lucas GM, Lechtzin N, Puryear DW et al. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26: 1127-33.
3. Kazmier FJ. A significant interaction between metronidazole and warfarin. Mayo Clin Proc 1976; 51: 782-4.
4. Gross R, Morgan AS, Kinky DE et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33: 289-95.
5. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; issue 3: CD004610.
6. Lautenbach E, Synnestvedt M, Weiner MG et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009; 30: 1186-92.
7. Lautenbach E, Synnestvedt M, Weiner MG et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010; 31: 47-53.
8. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
9. Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilisation studies. Eur J Clin Pharmacol 1996; 50: 27-30.
10. Rattanaumpawan P, Sutha P, Thamlikitkul V. Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures. Am J Infect Control 2010; 38: 38-43.